Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.bafnapharma.com | |
Market Cap | 231.36 Cr. | |
Enterprise Value(EV) | 251.35 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.55 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 63.25 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 27.83 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 3.51 | Calculated using Price: 97.80 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 2.37 Cr. | 23,656,335 Shares |
FaceValue | 10 | |
Company Profile | ||
Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984. |
1 Day |
|
+1.03% |
1 Week |
|
-3.17% |
1 Month |
|
-4.91% |
3 Month |
|
-6.81% |
6 Month |
|
-11.73% |
1 Year |
|
-34.34% |
2 Year |
|
-18.26% |
5 Year |
|
+320.65% |
10 Year |
|
+119.53% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 2.25 | 9.22 | -18.69 | -37.05 | -40.37 | -64.36 | -22.93 | 22.26 | 8.61 | |
Return on Capital Employed (%) | 9.15 | 12.56 | -0.04 | -5.98 | -6.97 | -20.90 | -2.95 | 10.62 | 8.39 | |
Return on Assets (%) | 0.57 | 2.99 | -6.58 | -10.49 | -11.17 | -15.90 | -1.96 | 7.40 | 5.83 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 69 | 72 | 59 | 45 | 41 | 21 | 51 | 57 | 63 | 66 | |
Non Curr. Liab. | 27 | 14 | 39 | 42 | 28 | 29 | 3 | 5 | 11 | 7 | |
Curr. Liab. | 126 | 100 | 87 | 81 | 59 | 71 | 17 | 24 | 16 | 34 | |
Minority Int. | |||||||||||
Equity & Liab. | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 106 | |
Non Curr. Assets | 66 | 68 | 65 | 90 | 79 | 72 | 35 | 37 | 39 | 43 | |
Curr. Assets | 149 | 117 | 119 | 77 | 48 | 48 | 36 | 50 | 51 | 63 | |
Misc. Exp. not W/O | 8 | 1 | |||||||||
Total Assets | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 106 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 178 | 143 | 85 | 65 | 47 | 44 | 42 | 71 | 85 | 74 | |
Other Income | 1 | 1 | 1 | 1 | 31 | 0 | 0 | 1 | 2 | 4 | |
Total Income | 179 | 144 | 87 | 66 | 78 | 44 | 43 | 72 | 87 | 78 | |
Total Expenditure | -156 | -117 | -83 | -70 | -82 | -57 | -41 | -61 | -74 | -68 | |
PBIDT | 23 | 26 | 4 | -4 | -4 | -13 | 1 | 11 | 14 | 10 | |
Interest | -12 | -12 | -12 | -11 | -7 | -2 | 0 | -1 | -1 | -1 | |
Depreciation | -8 | -5 | -4 | -4 | -4 | -3 | -3 | -4 | -5 | -5 | |
Taxation | -1 | 0 | 0 | 1 | -2 | -2 | |||||
Exceptional Items | -3 | -2 | 0 | ||||||||
PAT | 1 | 6 | -12 | -18 | -16 | -20 | -2 | 6 | 5 | 4 | |
Adjusted EPS | 1 | 3 | -7 | -10 | -7 | -8 | -8 | 2 | 2 | 2 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 35 | 1 | 9 | -3 | 20 | -7 | -1 | -34 | -14 | 8 | |
Cash Fr. Inv. | -6 | -5 | 56 | -1 | -14 | 38 | 4 | 33 | -5 | -5 | |
Cash Fr. Finan. | -11 | -14 | -66 | 4 | -5 | -31 | -2 | 7 | 12 | -4 | |
Net Change | 18 | -18 | 0 | 0 | 0 | 0 | 6 | -7 | -2 | ||
Cash & Cash Eqvt | 21 | 2 | 2 | 3 | 3 | 3 | 3 | 8 | 2 | 0 |
Wed, 01 Feb 2023
Board Meeting Intimation for Considering The Unaudited Results For The Nine Months Period And Quarter Ended 31.12.2022 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve the Unaudited Results for the Nine Months Period and Quarter ended 31.12.2022 |
Fri, 20 Jan 2023
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Bafna Pharmaceuticals Limited Awarded With MSME-ZED Certified GOLD CERTIFICATE Bafna Pharmaceuticals Limited is proud to announce that the Company has been awarded MSME ZED GOLD CERTFICATE by the Ministry of Micro Small & Medium Enterprises Government of India. |
Thu, 19 Jan 2023
Announcement under Regulation 30 (LODR)-Resignation of Director Resignation of Mr. Atul Sachdeva as an Non Executive Non Independent Director of the Company with effect from 13th January 2023. |
Fri, 03 Feb 2023 |
|
|
|
|
Thu, 02 Feb 2023 |
|